AIM ImmunoTech Announces Closing of its Rights Offering
· aim immunotech inc.
AI Briefing
- AIM ImmunoTech closes rights offering for $1.8 million.
- Company focused on late-stage pancreatic cancer treatment Ampligen research.
- Rintatolimod is a lethal and unmet global health problem.
Advertisement